Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first‐line, systemic chemotherapy

摘要: BACKGROUND. Few studies have assessed formally whether treatment outcomes improved substantially over the years for patients with advanced nonsmall cell lung cancer (NSCLC) enrolled in Phase III trials. The objective of current investigation was to determine time trends those trials. METHODS. The literature searched identify trials that addressed role chemotherapy regimens first-line setting NSCLC. Trends were tested by using multiple regression analysis. RESULTS. In total, 121 identified involved 42,768 263 arms and 11 best supportive care (BSC) arms, all which initiated between 1982 2002. Although number randomized proportion metastatic disease had increased years, a poor performance status who accrued into decreased. Cisplatin-based been investigated most frequently during period. analysis revealed significant improvement median survival progression annual prolongations 0.1203 months (3.609 days) 0.0617 (1.851 days), respectively (P< .0001 P < .0130, respectively). In addition, use cisplatin carboplatin associated significantly prolongation. received BSC also progressively (P = .0487). CONCLUSIONS. The NSCLC slowly but steadily time, although main factors responsible this remain unknown. Nonetheless, results suggested novel targets new agents will be required future fight against Cancer 2007 © American Society.